Ontology highlight
ABSTRACT: Background
Women harboring mutations in breast cancer susceptibility genes are at increased lifetime risk of developing breast cancer and are faced with decisions about risk management, including whether to undergo high-risk screening or risk-reducing mastectomy (RRM). National guidelines recommend BRCA1 or BRCA2 mutation carriers consider RRM, but that carriers of moderate penetrance mutations (e.g., ATM or CHEK2) should be managed based on family history. We aimed to investigate determinants of decision for RRM, and hypothesized that mutation status, age, family history, partner status, and breast cancer would impact RRM decision making.Methods
We performed a retrospective study assessing RRM decisions for 279 women.Results
Women with BRCA and moderate penetrance gene mutations, a personal history of breast cancer, or a first degree relative with a history of breast cancer were more likely to undergo RRM. Breast cancer status and age showed an interaction effect such that women with breast cancer were less likely to undergo RRM with increasing age.Conclusion
Although national guidelines do not recommend RRM for moderate penetrance carriers, the rates of RRM for this population approached those for BRCA mutation carriers. Further insights are needed to better support RRM decision-making in this population.
SUBMITTER: Comeaux JG
PROVIDER: S-EPMC9544212 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Comeaux Jacob G JG Culver Julie O JO Lee John E JE Dondanville Danielle D McArthur Heather L HL Quinn Emily E Gorman Nicholas N Ricker Charité C Li Ming M Lerman Caryn C
Molecular genetics & genomic medicine 20220825 10
<h4>Background</h4>Women harboring mutations in breast cancer susceptibility genes are at increased lifetime risk of developing breast cancer and are faced with decisions about risk management, including whether to undergo high-risk screening or risk-reducing mastectomy (RRM). National guidelines recommend BRCA1 or BRCA2 mutation carriers consider RRM, but that carriers of moderate penetrance mutations (e.g., ATM or CHEK2) should be managed based on family history. We aimed to investigate determ ...[more]